Therapeutic Asset Ratings
297 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Irinotecan
Endometrial Serous Adenocarcinoma
Roswell Park Cancer Institute
P2
BB
(64)
Pembrolizumab
Richter Syndrome
Roswell Park Cancer Institute
P2
BB
(64)
Rapamycin
Recurrent Adult Acute Lymphoblastic Leukemia
Roswell Park Cancer Institute
P2
BB
(64)
TESTOSTERONE CIPIONATE
Castration-Resistant Prostate Carcinoma
Roswell Park Cancer Institute
P2
BB
(64)
Cyclophosphamide
Fallopian Tube Endometrioid Adenocarcinoma
Roswell Park Cancer Institute
P2
B
(63)
Cyclophosphamide
Primary Peritoneal Serous Adenocarcinoma
Roswell Park Cancer Institute
P2
B
(63)
Epirubicin
Fallopian Tube Serous Adenocarcinoma
Roswell Park Cancer Institute
P2
B
(63)
Epirubicin
Ovarian Clear Cell Adenocarcinoma
Roswell Park Cancer Institute
P2
B
(63)
Epirubicin
Primary Peritoneal Serous Adenocarcinoma
Roswell Park Cancer Institute
P2
B
(63)
Evomela
Acute Myeloid Leukemia in Remission
Roswell Park Cancer Institute
P2
B
(63)
Evomela
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Roswell Park Cancer Institute
P2
B
(63)
Montanide Isa 51
Stage III Lung Cancer AJCC v8
Roswell Park Cancer Institute
P2
B
(63)
Pembrolizumab
Fallopian Tube Serous Adenocarcinoma
Roswell Park Cancer Institute
P2
B
(63)
Pembrolizumab
Ovarian Clear Cell Adenocarcinoma
Roswell Park Cancer Institute
P2
B
(63)
Pembrolizumab
Ovarian Serous Adenocarcinoma
Roswell Park Cancer Institute
P2
B
(63)
Pembrolizumab
Primary Peritoneal Serous Adenocarcinoma
Roswell Park Cancer Institute
P2
B
(63)
(+)-VINCRISTINE
Endometrial Serous Adenocarcinoma
Roswell Park Cancer Institute
P2
B
(63)
Photofrin II
Non-Small Cell Lung Carcinoma
Roswell Park Cancer Institute
P1/2
B
(63)
Cediranib
Clear Cell Renal Cell Carcinoma
Roswell Park Cancer Institute
P3
B
(62)
Pembrolizumab
Epithelial Ovarian Cancer
Roswell Park Cancer Institute
P3
B
(62)
Cyclophosphamide
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Roswell Park Cancer Institute
P2
B
(62)
Evomela
Waldenstrom Macroglobulinemia
Roswell Park Cancer Institute
P2
B
(62)
Irinotecan
Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
Roswell Park Cancer Institute
P2/3
B
(62)
(+)-VINCRISTINE
Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
Roswell Park Cancer Institute
P2/3
B
(62)
TESTOSTERONE UNDECYLATE
Prostate Cancer
Roswell Park Cancer Institute
P4
B
(61)
Showing 51 to 75 of 297 assets
Previous
Page 3 of 12
Next